Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”),
a clinical-stage biotechnology company leading the discovery and
development of the next generation of allosteric small molecule
therapies, today announced participation in the upcoming Public
Ventures Discovery Day on March 19, 2024 at Old Parkland in Dallas,
TX.
Public
Ventures Discovery DayDate: Tuesday,
March 19, 2024Presentation: 2:30
PM CSTLocation: Pecan Room, Old Parkland,
3819 Maple Avenue, Dallas TX 75219
A video replay of the fireside chat will be
available shortly after the conclusion of the event on the
Investors and Media section of the company’s website at
www.gaintherapeutics.com.
Public Ventures, LLC, a wholly owned subsidiary
of MDB Capital Holdings, LLC, (NASDAQ: MDBH), is the first
invite-only investor community and self-clearing broker-dealer
platform dedicated to backing visionary public companies with the
potential to become market leaders in their technology
category.
Discovery Day is a unique event for investors to
learn about a curated group of venture-stage, deep-tech companies;
share feedback and questions with company leaders; and connect with
like-minded investors.
To register for Discovery Day, please email
community@publicventures.com. Please note that spots are limited,
and attendance preference will be given to existing MDBH
shareholders.
About GT-02287
Gain Therapeutics’ lead drug candidate,
GT-02287, is in clinical development for the treatment of GBA1
Parkinson’s disease (GBA1-PD). The orally administered,
brain-penetrant small molecule is an allosteric protein modulator
that restores the function of the lysosomal protein enzyme
glucocerebrosidase (GCase) which becomes misfolded and impaired due
to a GBA1 gene mutation, the most common genetic abnormality
associated with PD. In preclinical models of PD, GT-02287 restored
GCase enzymatic function, reduced aggregated α-synuclein,
neuroinflammation and neuronal death, increased dopamine levels and
improved motor function. Additionally, GT-02287 significantly
reduced plasma neurofilament light chain (NfL) levels, an emerging
biomarker for neurodegeneration.
Gain’s lead program in Parkinson’s disease has
been awarded funding support from The Michael J. Fox Foundation for
Parkinson’s Research (MJFF) and The Silverstein Foundation for
Parkinson’s with GBA, as well as from the Eurostars-2 joint program
with co-funding from the European Union Horizon 2020 research and
Innosuisse – Swiss Innovation Agency.
About GBA1 Parkinson’s
Disease
GBA1 Parkinson’s disease is caused by mutations
in the GBA1 gene, found in up to 15% of patients with Parkinson’s
disease and making it the primary genetic risk factor. The mutation
causes dysfunctional misfolding of the lysosomal enzyme
glucocerebrosidase (GCase), reducing its activity in the brain and
leading to the subsequent accumulation of α-synuclein and
degeneration of dopamine-containing nerve cells. Patients with
GBA1-PD tend to have earlier onset and faster symptom progression
than those with sporadic PD, a progressive neurodegenerative
disease characterized by a motor syndrome consisting of
bradykinesia (slowness of movement), rigidity, resting tremors, and
postural instability. With current therapies treating only the
symptoms of Parkinson’s disease without affecting the underlying
progression of the disease, there is an unmet need to develop novel
disease-modifying therapies such as GT-02287 that have the
potential to slow or stop disease progression and help improve
outcomes in this patient population.
About Gain Therapeutics,
Inc.
Gain Therapeutics, Inc. is a clinical-stage
biotechnology company leading the discovery and development of next
generation allosteric therapies. Gain’s lead drug candidate
GT-02287 for the treatment of GBA1 Parkinson’s disease, is
currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology,
proprietary algorithms and supercomputer-powered physics-based
models, the company’s Magellan™ drug discovery platform can
identify novel allosteric binding sites on disease-implicated
proteins, pinpointing pockets that cannot be found or drugged with
current technologies. Magellan™ is the next generation of Gain’s
original SEE-Tx® (Site-Directed Enzyme Enhancement Therapy)
platform, which was enhanced and expanded with new AI and
machine-learning tools and virtual screening capabilities to access
the emerging on-demand compound libraries covering vast chemical
spaces of over 50 billion compounds.
Gain’s unique approach enables the discovery of
novel, allosteric small molecule modulators that can restore or
disrupt protein function. Deploying its highly advanced platform,
Gain is accelerating drug discovery and unlocking novel
disease-modifying treatments for untreatable or difficult-to-treat
disorders including neurodegenerative diseases, rare genetic
disorders and oncology. For more information, please
visit GainTherapeutics.com and follow us
on LinkedIn.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements in this press release other than
statements of historical facts are “forward-looking statements”. In
some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "goal, " "intend,"
"seek, " "potential" or "continue," the negative of these terms and
variations of these words or similar expressions that are intended
to identify forward-looking statements, although not all
forward-looking statements contain these words. Forward-looking
statements in this press release include, but are not limited to,
statements regarding: the development of the Company’s current or
future product candidates including GT-02287; expectations
regarding the timing of results from a Phase 1 clinical study for
GT-02287; and the potential therapeutic and clinical benefits of
the Company’s product candidates. These forward-looking statements
are based on the Company’s expectations and assumptions as of the
date of this press release. Each of these forward-looking
statements involves risks and uncertainties that could cause the
Company’s preclinical and future clinical development programs,
future results or performance to differ materially from those
expressed or implied by the forward-looking statements. These
statements are not historical facts but instead represent the
Company's belief regarding future results, many of which, by their
nature, are inherently uncertain and outside the Company's control.
Many factors may cause differences between current expectations and
actual results, including the impacts of the post-COVID-19
environment and other global and macroeconomic conditions on the
Company’s business; clinical trials and financial position;
unexpected safety or efficacy data observed during preclinical
studies or clinical trials, clinical trial site activation or
enrollment rates that are lower than expected; changes in expected
or existing competition; changes in the regulatory environment; the
uncertainties and timing of the regulatory approval process; and
unexpected litigation or other disputes. Other factors that may
cause the Company’s actual results to differ from those expressed
or implied in the forward-looking statements in this press release
are identified in the section titled “Risk Factors,” in the
Company’s Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 23, 2023 and its other documents
subsequently filed with or furnished to the Securities and Exchange
Commission from time to time. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. The Company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
Investor Contact:
CORE IR(516)
222-2560 ir@gaintherapeutics.com
Media Contacts:
Russo PartnersNic Johnson and Elio
Ambrosionic.johnson@russopartnersllc.comelio.ambrosio@russopartnersllc.com(212)
845-4242
Gain Therapeutics (NASDAQ:GANX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Gain Therapeutics (NASDAQ:GANX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024